The ZEN30 Futurity™ is Aptar Pharma’s innovative pMDI valve, designed and optimized for low Global Warming Potential (GWP) formulations. It offers an optimized valve technology for delivering more sustainable respiratory medications, contributing to reduced environmental impact while ensuring optimal performance. Based on a 35-year tradition and a deep understanding of valve technology, the ZEN30 Futurity™ is designed specifically for a seamless transition to low GWP propellants and to ensure reliable and robust performance.
The ZEN30 Futurity™ valve platform has been optimized and refined to be compatible with the leading two low GWP propellants: HFA152a and HFO1234ze. While the materials of several components have been changed to ensure optimal compatibility with the new propellants, the external valve geometry has been maintained to ensure compatibility with other parts of the container closure system and subsequent pMDI filling lines. This ensures a seamless transition to low GWP pMDIs for our clients.
By choosing the ZEN30 Futurity™, you can de-risk and accelerate your low GWP pMDI development. Our proprietary elastomers and gaskets have been developed and manufactured within our dedicated in-house elastomer facility with an objective to lower the levels of extractables within our valves and thus reduce the potential for leachables, whilst maintaining a reliable supply chain and ensuring regulatory compliance.
Our ZEN30 Futurity™ product range has been simplified to ensure the same valve can be used with formulations containing either HFA152a or HFO1234ze-based propellants.





